Your browser doesn't support javascript.
Development of an LNP-Encapsulated mRNA-RBD Vaccine against SARS-CoV-2 and Its Variants.
Liu, Cong; Rcheulishvili, Nino; Shen, Zhigao; Papukashvili, Dimitri; Xie, Fengfei; Wang, Ziqian; Wang, Xingyun; He, Yunjiao; Wang, Peng George.
  • Liu C; School of Medicine, Southern University of Science and Technology, Shenzhen 518000, China.
  • Rcheulishvili N; School of Medicine, Southern University of Science and Technology, Shenzhen 518000, China.
  • Shen Z; School of Medicine, Southern University of Science and Technology, Shenzhen 518000, China.
  • Papukashvili D; School of Medicine, Southern University of Science and Technology, Shenzhen 518000, China.
  • Xie F; School of Medicine, Southern University of Science and Technology, Shenzhen 518000, China.
  • Wang Z; School of Medicine, Southern University of Science and Technology, Shenzhen 518000, China.
  • Wang X; School of Medicine, Southern University of Science and Technology, Shenzhen 518000, China.
  • He Y; School of Medicine, Southern University of Science and Technology, Shenzhen 518000, China.
  • Wang PG; School of Medicine, Southern University of Science and Technology, Shenzhen 518000, China.
Pharmaceutics ; 14(5)2022 May 20.
Article in English | MEDLINE | ID: covidwho-1953859
ABSTRACT
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is undoubtedly the most challenging pandemic in the current century and remains a global health emergency. As the number of COVID-19 cases in the world is on the rise and variants continue to emerge, there is an urgent need for vaccines. Among all immunization approaches, mRNA vaccines have demonstrated more promising results in response to this challenge. Herein, we designed an mRNA-based vaccine encoding the receptor-binding domain (RBD) of SARS-CoV-2 encapsulated in lipid nanoparticles (LNPs). Intramuscular (i.m.) administration of the mRNA-RBD vaccine elicited broad-spectrum neutralizing antibodies and cellular responses against not only the wild-type SARS-CoV-2 virus but also Delta and Omicron variants. These results indicated that two doses of mRNA-RBD immunization conferred a strong immune response in mice against the wild-type SARS-CoV-2, while the booster dose provided a sufficient immunity against SARS-CoV-2 and its variants. Taken together, the three-dose regimen strategy of the mRNA-RBD vaccine proposed in the present study appears to be a promising reference for the development of mRNA vaccines targeting SARS-CoV-2 variants.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines / Variants Language: English Year: 2022 Document Type: Article Affiliation country: Pharmaceutics14051101

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines / Variants Language: English Year: 2022 Document Type: Article Affiliation country: Pharmaceutics14051101